Compare AMP & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMP | BDX |
|---|---|---|
| Founded | 1894 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3B | 54.6B |
| IPO Year | 2009 | 1998 |
| Metric | AMP | BDX |
|---|---|---|
| Price | $493.89 | $195.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 16 |
| Target Price | ★ $554.64 | $195.57 |
| AVG Volume (30 Days) | 400.0K | ★ 1.3M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | 1.38% | ★ 2.14% |
| EPS Growth | ★ 9.77 | N/A |
| EPS | ★ 21.64 | 1.59 |
| Revenue | $18,911,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $6.05 | $2.34 |
| P/E Ratio | ★ $22.81 | $123.42 |
| Revenue Growth | 5.49 | ★ 8.24 |
| 52 Week Low | $422.37 | $140.11 |
| 52 Week High | $572.56 | $213.08 |
| Indicator | AMP | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 62.05 |
| Support Level | $483.56 | $195.63 |
| Resistance Level | $509.51 | $213.08 |
| Average True Range (ATR) | 10.06 | 3.77 |
| MACD | 1.88 | 0.88 |
| Stochastic Oscillator | 47.64 | 77.63 |
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating profit from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.